Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
2026-09-29 09:35
•Thomas Niel •The Motley Fool
•••• • Axe Cap view
Teva’s Turnaround Signals Potential But Watch Rand Exposure
Teva Pharmaceutical’s pivot from generic to branded drugs has sparked a major share rebound, but South African investors should weigh currency risks.
Teva has flipped its script, moving from generic reliance to branded drugs, which offer higher margins and more sustainable growth. Cutting net debt by nearly $5.5 billion and securing an investment-grade credit rating adds credibility to this turnaround. The strong earnings growth projected through 2027 is appealing, especially at a forward price-earnings ratio under 13. For South African investors, the tricky part is the rand. With the rand volatile against the dollar, gains in Teva denominated in USD can be eroded quickly if the rand weakens, or boosted if it strengthens. This makes timing and currency management crucial. Those watching the JSE might not find a direct equivalent, but sectors like healthcare and large-cap tech carry similar long-term value stories. Teva is worth tracking for global exposure, but not without caution given FX swings. If US dollar strength fades or the pipeline disappoints, Teva’s valuation could come under pressure. this is just our opinion and not financial advice
Watch Teva closely for entry on any rand-dollar softness and buy selectively, but hedge currency risk or limit exposure. Avoid chasing after big moves, and consider local healthcare alternatives for lower FX risk.
- TEVA
- USD/ZAR
- USD/ZAR volatility eroding returns
- Potential setbacks in Teva's late-stage drug pipeline
6/10
Teva Pharmaceutical has surged 110% in the last year, hitting a 52-week high of $40.79 per share, driven by its pivot from generic to branded drugs. The company's innovative portfolio of three branded products is projected to generate $3.7 billion in 2026 revenue, while net debt has decreased from $18.4 billion (end of 2022) to $12.9 billion, earning a credit rating upgrade to investment-grade status. With peak annual sales of $10 billion anticipated from its late-stage pipeline and earnings expected to grow 40.7% between 2026-2027, analysts view the stock as undervalued at 12.9x forward earnings.
Our take is based on reporting first published by The Motley Fool.